聚乳酸共聚物复合缓释药物的材料特征与实验应用

Characteristics and experimental application of polylactic acid copolymer composite sustained-release drug materials

背景:聚乳酸共聚物复合药物缓释材料能够降低药物的毒副作用,延长药物作用时间,提高药物治疗效果,是目前药物研究的热点之一。目的:明确各种聚乳酸共聚物复合药物缓释材料的特征以及实验应用效果。方法:将不同种类的药物与聚乳酸进行共聚结合形成聚乳酸共聚物复合药物缓释材料,分析多种聚乳酸共聚物复合药物缓释材料的释药特征,并分析动物实验研究中聚乳酸共聚物复合缓释药物材料的治疗效果。结果与结论:研究发现多种治疗药物均可以与聚乳酸结合形成聚乳酸共聚物复合药物缓释材料系统,其中包括抗肿瘤类药物、抗菌、抗病毒类药物、抗结核类药物、心脑血管疾病防治类药物以及代谢类药物。这些药物与聚乳酸结合形成共聚物缓释系统后,可以延长药物作用时间,有效稳定血药浓度,达到靶向性治疗的作用,明显提高药物治疗作用效果。

BACKGROUND： Polylactic acid copolymer composite sustained-release drug materials can reduce the toxic side effects of drugs, extend the action time and improve the effect of the drugs, and it is the hot spot of the drug research recently. OBJECTIVE： To identify the characteristics and experimental application of various polylactic acid copolymer composite sustained-release drug materials. METHODS： Different types of drugs were copolymerized with the polylactic acid to form the polylactic acid copolymer composite sustained-release drug materials, and the drug release characteristics andthe treatment effect of various polylactic acid copolymer composite sustained-release drug materials in the animal experimental studies were analyzed. RESULTS AND CONCLUSION： Studies have found that many types of drug can be copolymerized with the polylactic acid and form the polylactic acid copolymer composite sustained-release drug material system, including the anti-tumor drugs, anti-bacterial drugs, anti-viral drugs, anti-tuberculosis drugs, drugs for the prevention and treatment of cardiovascular and cerebrovascular diseases and the metabolic drugs. The drugs above can prolong the action time, effectively stabilizethe plasma concentration, obtain the role of targeted therapy and significantly improve the treatment effect after copolymerized with the polylactic acid and form the polylactic acid copolymer composite sustained-release drug material system.